m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05477
|
[1] | |||
m6A modification
MALAT1
MALAT1
FTO
Demethylation
 : m6A sites
Direct
Enhancement
Non-coding RNA
MALAT1
Regulated Target
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | |||
| m6A Target | Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) | LncRNA | View Details | ||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | m6A modification is co-regulated by METTL3 and FTO in cadmium-treated cells. Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), LncRNA-PVT1 and m6A modification could be key nodes for cadmium-induced oxidative damage, and highlight their importance as promising preventive and therapeutic targets in cadmium toxicity. | ||||
| Responsed Disease | Kidney failure | ICD-11: GB6Z | |||
| Cell Process | Cell viability | ||||
In-vitro Model |
NIT-1 | Insulin tumor | Mus musculus | CVCL_3561 | |
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| GB6Z: Kidney failure | 1 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
 Compound Name |
LHW090 | Phase 2 | [2] | |
|---|---|---|---|---|
| External Link | ||||
References